<p>Medtronic plc has announced additional data from the EMBOLISE clinical trial, a multicenter, prospective, and randomized study in the United States evaluating the OnyxTM Liquid Embolic System (LES) for middle meningeal artery (MMA) embolization in patients with symptomatic subacute or chronic subdural hematoma (cSDH). The trial compared MMA embolization using Onyx LES to observation only. Results showed that the Test arm (Onyx MMA embolization) met the pre-specified 90-day primary effectiveness endpoint and demonstrated a positive trend in 180-day imaging for hematoma improvement compared to the control arm. Previous findings from the Surgery Cohort, published in the New England Journal of Medicine in November 2024, indicated a 63% reduction in treatment with surgery plus MMA embolization compared to surgery alone. The data have been presented at multiple major conferences and published in journals including NEJM, Radiology, and JNIS. Medtronic announced an indication expansion in the U.S. for the Onyx 18 and 34 liquid embolic system as an adjunct to surgery in December 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief on February 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

LABD

Reuters

Direxion S&P Biotech Bear 3X

iShares US Medical Devices

iShares Biotechnology ETF

ALPS Medical Breakthrough

SPDR S&P Health Equip

Medtronic

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

SPDR S&P Biotech

Medtronic Announces Positive EMBOLISE Trial Results for Onyx LES in Chronic Subdural Hematoma